1. Home
  2. ULBI vs TCRX Comparison

ULBI vs TCRX Comparison

Compare ULBI & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ULBI
  • TCRX
  • Stock Information
  • Founded
  • ULBI 1990
  • TCRX 2018
  • Country
  • ULBI United States
  • TCRX United States
  • Employees
  • ULBI N/A
  • TCRX N/A
  • Industry
  • ULBI Industrial Machinery/Components
  • TCRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ULBI Miscellaneous
  • TCRX Health Care
  • Exchange
  • ULBI Nasdaq
  • TCRX Nasdaq
  • Market Cap
  • ULBI 98.1M
  • TCRX 90.5M
  • IPO Year
  • ULBI 1992
  • TCRX 2021
  • Fundamental
  • Price
  • ULBI $5.05
  • TCRX $1.27
  • Analyst Decision
  • ULBI Strong Buy
  • TCRX Strong Buy
  • Analyst Count
  • ULBI 1
  • TCRX 7
  • Target Price
  • ULBI $14.00
  • TCRX $9.86
  • AVG Volume (30 Days)
  • ULBI 62.5K
  • TCRX 389.5K
  • Earning Date
  • ULBI 05-09-2025
  • TCRX 05-06-2025
  • Dividend Yield
  • ULBI N/A
  • TCRX N/A
  • EPS Growth
  • ULBI N/A
  • TCRX N/A
  • EPS
  • ULBI 0.31
  • TCRX N/A
  • Revenue
  • ULBI $173,275,000.00
  • TCRX $4,421,000.00
  • Revenue This Year
  • ULBI $35.52
  • TCRX $47.30
  • Revenue Next Year
  • ULBI N/A
  • TCRX $74.30
  • P/E Ratio
  • ULBI $12.84
  • TCRX N/A
  • Revenue Growth
  • ULBI 2.74
  • TCRX N/A
  • 52 Week Low
  • ULBI $4.07
  • TCRX $1.02
  • 52 Week High
  • ULBI $13.39
  • TCRX $9.69
  • Technical
  • Relative Strength Index (RSI)
  • ULBI 58.57
  • TCRX 37.62
  • Support Level
  • ULBI $4.36
  • TCRX $1.32
  • Resistance Level
  • ULBI $4.60
  • TCRX $1.65
  • Average True Range (ATR)
  • ULBI 0.24
  • TCRX 0.12
  • MACD
  • ULBI 0.11
  • TCRX -0.02
  • Stochastic Oscillator
  • ULBI 85.86
  • TCRX 0.00

About ULBI Ultralife Corporation

Ultralife Corp provides products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government and defense, medical, safety and security, energy, and industrial sectors. The company designs, manufactures, installs, and maintains power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom-engineered systems. The company's segments include Battery and Energy Products, and Communications Systems. It generates maximum revenue from the Battery and Energy Products segment, and from the U.S. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, and various other non-rechargeable batteries.

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Share on Social Networks: